The high toxicity and low specificity of the existing Arf1 inhibitors, such as Golgicide A (GCA), Brefeldin A (BFA), and Exo2 have greatly limited their translational potential and related research.[15, 16, 17, 18] Genetic screens in model organisms have been extensively used to study gene's biological functions.[19] To date, the utilization of such screens for the identification of target genes associated with tumor immunity has been limited. The gene discussed is ARF1; the disease is neoplasm.